ProQR Therapeutics initiated with an Outperform at Oppenheimer

Oppenheimer analyst Andreas Argyrides initiated coverage of ProQR Therapeutics (PRQR) with an Outperform rating and $15 price target The firm says the Axiomer RNA editing platform leads the next wave of genomics medicine by offering a precise, reversible alternative to DNA-based therapies. With first-in-human competitor data in October validating RNA-editing, ProQR is poised to further capitalize on its “differentiated” development strategy focusing on diseases with genetically known protective mutations, the analyst tells investors in a research note. Opco expects multiple catalysts this year from competitors and ProQR.